CoImmune, Inc. Announces Closing of $45 Million Series A Financing
DURHAM, N.C., Nov. 10, 2020 (GLOBE NEWSWIRE) — CoImmune, Inc., an immuno-oncology company developing cell-based therapeutics to treat unmet medical needs in blood-borne and solid tumor indications, today announced the closing of a $45M Series A financing. CoImmune will use the proceeds from the financing …
Read More